France Rheumatoid Arthritis Therapeutics Market Size & Outlook

The rheumatoid arthritis therapeutics market in France is expected to reach a projected revenue of US$ 1,543.3 million by 2030. A compound annual growth rate of 5.1% is expected of France rheumatoid arthritis therapeutics market from 2024 to 2030.
Revenue, 2023 (US$M)
$1,087.9
Forecast, 2030 (US$M)
$1,543.3
CAGR, 2024 - 2030
5.1%
Report Coverage
France

France rheumatoid arthritis therapeutics market, 2018-2030 (US$M)

France

Related Markets

France rheumatoid arthritis therapeutics market highlights

  • The France rheumatoid arthritis therapeutics market generated a revenue of USD 1,087.9 million in 2023 and is expected to reach USD 1,543.3 million by 2030.
  • The France market is expected to grow at a CAGR of 5.1% from 2024 to 2030.
  • In terms of segment, biopharmaceuticals was the largest revenue generating molecule in 2023.
  • Biopharmaceuticals is the most lucrative molecule segment registering the fastest growth during the forecast period.


Rheumatoid arthritis therapeutics market data book summary

Market revenue in 2023USD 1,087.9 million
Market revenue in 2030USD 1,543.3 million
Growth rate5.1% (CAGR from 2023 to 2030)
Largest segmentBiopharmaceuticals
Fastest growing segmentBiopharmaceuticals
Historical data2018 - 2022
Base year2023
Forecast period2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationPharmaceuticals, Biopharmaceuticals
Key market players worldwideBoehringer Ingelheim, Novartis AG ADR, Regeneron Pharmaceuticals Inc, Pfizer Inc, Bristol-Myers Squibb Co, Roche Holding AG, UCB SA, Johnson & Johnson, Amgen Inc, AbbVie Inc


Other key industry trends

  • In terms of revenue, France accounted for 4.4% of the global rheumatoid arthritis therapeutics market in 2023.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Europe, UK rheumatoid arthritis therapeutics market is projected to lead the regional market in terms of revenue in 2030.
  • UK is the fastest growing regional market in Europe and is projected to reach USD 2,119.5 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Rheumatoid Arthritis Therapeutics Market Companies

Name Profile # Employees HQ Website

France rheumatoid arthritis therapeutics market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to rheumatoid arthritis therapeutics market will help companies and investors design strategic landscapes.


Biopharmaceuticals was the largest segment with a revenue share of 88.73% in 2023. Horizon Databook has segmented the France rheumatoid arthritis therapeutics market based on pharmaceuticals, biopharmaceuticals covering the revenue growth of each sub-segment from 2018 to 2030.


The France rheumatoid arthritis therapeutics market is witnessing significant advancements with the collaboration between Gilead Sciences, Inc. and EVOQ Therapeutics, Inc., announced in January 2023. This collaboration aims to leverage EVOQ's innovative Nano Disc technology.

This technology can potentially revolutionize the treatment landscape for autoimmune diseases by offering targeted and effective therapeutic solutions. Gilead and EVOQ's collaboration involves joint efforts in preclinical development, with Gilead having the option to exclusively license rights to EVOQ's Nano Disc technology for developing product candidates targeting RA and lupus indications.

Furthermore, Gilead will lead clinical development and commercialization, highlighting the company's commitment to advancing innovative treatments for autoimmune diseases in the French market. This collaboration signifies a strategic move toward personalized and targeted therapies, addressing the underlying causes of RA and lupus.

Reasons to subscribe to France rheumatoid arthritis therapeutics market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of France rheumatoid arthritis therapeutics market databook

  • Our clientele includes a mix of rheumatoid arthritis therapeutics market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the France rheumatoid arthritis therapeutics market, including forecasts for subscribers. This country databook contains high-level insights into France rheumatoid arthritis therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

France rheumatoid arthritis therapeutics market size, by molecule, 2018-2030 (US$M)

France Rheumatoid Arthritis Therapeutics Market Share, 2023 & 2030 (US$M)

France rheumatoid arthritis therapeutics market size, by molecule, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more